ABSTRACT
INTRODUCTION Machine learning applied to neuroimaging can help with medical diagnosis and early detection by identifying biomarkers of subtle changes in brain structure and function. The effectiveness of advanced diffusion MRI (dMRI) imaging methods for pre-dementia classification remains largely unexplored, particularly when combined with CSF biomarkers.
METHODS We implemented XGBoost machine learning models to evaluate the classification potential of dMRI parameters (derived using NODDI, C-NODDI, MAP, or SMI), CSF biomarkers of Alzheimer’s pathology (Tau, pTau, Aβ42, Aβ40), and pairwise dMRI + CSF combinations in distinguishing cognitive normality from mild cognitive impairment.
RESULTS MAP-RTAP (AUC=0.78) and pTau/Aβ42 (AUC=0.76) were the best performing individual biomarkers. Combining C-NODDI-C-NDI and Aβ42/Aβ40 achieved the highest performance (AUC=0.84) and accuracy (0.84), while other combinations optimized either sensitivity (0.93) or specificity (0.88).
DISCUSSION dMRI biomarkers demonstrate comparable performance to CSF biomarkers, with notable improvements achieved when combined. This study highlights dMRI’s potential for enhancing early AD detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Intramural Research Program of the National Institute on Aging of the National Institutes of Health. Data collection and sharing for this project were supported by the Alzheimer's Disease Neuroimaging Initiative (ADNI) through funding from the National Institutes of Health (Grant U01 AG024904) and the Department of Defense (DOD ADNI, award number W81XWH-12-2-0012). ADNI is primarily funded by the National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering, with additional support from the Canadian Institutes of Health Research for clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). Generous financial support has also been provided by various organizations, including AbbVie, the Alzheimer's Association, the Alzheimer's Drug Discovery Foundation, Araclon Biotech, BioClinica, Inc., Biogen, Bristol-Myers Squibb Company, CereSpir, Inc., Cogstate, Eisai Inc., Elan Pharmaceuticals, Inc., Eli Lilly and Company, EuroImmun, F. Hoffmann-La Roche Ltd. and its affiliate Genentech, Inc., Fujirebio, GE Healthcare, IXICO Ltd., Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development LLC, Lumosity, Lundbeck, Merck & Co., Inc., Meso Scale Diagnostics, LLC, NeuroRx Research, Neurotrack Technologies, Novartis Pharmaceuticals Corporation, Pfizer Inc., Piramal Imaging, Servier, Takeda Pharmaceutical Company, and Transition Therapeutics. The Northern California Institute for Research and Education serves as the grantee organization, while the Alzheimer's Therapeutic Research Institute at the University of Southern California coordinates the study. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in the present study were obtained from the ADNI cohort: https://adni.loni.usc.edu/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All processed data produced in the present study are available upon reasonable request to the authors and the ADNI committee.
